国际口腔医学杂志

国际口腔医学杂志 ›› 2018, Vol. 45 ›› Issue (2): 155-161.doi: 10.7518/gjkq.2018.02.007

• 口腔黏膜专栏 • 上一篇    下一篇

天疱疮的免疫抑制剂治疗方法

姚懿桓, 王冏珂, 赵奎, 时玉洁, 曾昕, 陈谦明   

  1. 口腔疾病研究国家重点实验室 国家口腔疾病临床医学研究中心
    四川大学华西口腔医院口腔黏膜病科 成都 610041
  • 收稿日期:2017-07-31 修回日期:2017-12-04 出版日期:2018-03-01 发布日期:2018-03-01
  • 通讯作者: 曾昕,教授,博士,Email：zengxin22@163.com
  • 作者简介:姚懿桓,硕士,Email：525218951@qq.com
  • 基金资助:
    国家自然科学基金（81472533）; 国家卫生和计划生育委员会公益性行业专项（201502018）

Immunosuppressive adjuvant therapy for pemphigus

Yao Yihuan, Wang Jiongke, Zhao Kui, Shi Yujie, Zeng Xin, Chen Qianming   

  1. State Key Laboratory of Oral Diseases &National Clinical Research Center for Oral Diseases &Dept. of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
  • Received:2017-07-31 Revised:2017-12-04 Online:2018-03-01 Published:2018-03-01
  • Supported by:
    This study was supported by National Natural Science Foundation of China (81472533) and Nonprofit Industry Research Sepecific Fund of National Health and Family Planning Commission of China (201502018).

RichHTML

15

PDF (PC)

591

摘要： 天疱疮是一种累及皮肤及黏膜的严重的慢性自身免疫大疱性疾病。目前,糖皮质激素作为治疗天疱疮的首选药物,在控制病情的同时也可能引起各种并发症。为减轻激素治疗的不良反应,常需与免疫抑制剂类药物联合运用或采用其他疗法。因此,笔者就天疱疮的免疫抑制剂疗法作一综述。

关键词: 天疱疮, 免疫抑制剂, 治疗

Abstract: Pemphigus is a severe, chronic, autoimmune bullous disease that affects the skin and mucous membranes. To date, glucocorticoidis the first treatment medicine for pemphigus. Nevertheless, the use of glucocorticoid may result in adverse effects during treatment of this disease. Therefore, several immunosuppressive adjuvant therapies or non-medicinal therapies should be adopted to relieve the side effects of glucocorticoid. Thus, we reviewed the immunosuppressive therapy in this article.

Key words: pemphigus, immunosuppressants, therapy

中图分类号: 

  • R781.5+9
[1] Bystryn JC.Adjuvant therapy of pemphigus[J]. Arch Dermatol, 1984, 120(7):941-951.
[2] 江潞, 陈谦明. 天疱疮的糖皮质激素治疗[J]. 国外医学口腔医学分册, 2004, 31(6):478-480.
Jiang L, Chen QM.The glucocorticoid therapy of pemphigus[J]. Foreign Med Sci: Stomatol, 2004, 31(6):478-480.
[3] Rosenberg FR, Sanders S, Nelson CT.Pemphigus: a 20-year review of 107 patients treated with cortico-steroids[J]. Arch Dermatol, 1976, 112(7):962-970.
[4] Schiavo AL, Puca RV, Ruocco V, et al.Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: facts and controversies[J]. Clin Dermatol, 2010, 28(3):337-343.
[5] Meurer M.Immunosuppressive therapy for autoim-mune bullous diseases[J]. Clin Dermatol, 2012, 30(1):78-83.
[6] Sandborn WJ.State-of-the-art: immunosuppression and biologic therapy[J]. Dig Dis, 2010, 28(3):536-542.
[7] Anstey AV, Wakelin S, Reynolds NJ, et al.Guidelines for prescribing azathioprine in dermatology[J]. Br J Dermatol, 2004, 151(6):1123-1132.
[8] Weinshilboum RM, Sladek SL.Mercaptopurine phar-macogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity[J]. Am J Hum Genet, 1980, 32(5):651-662.
[9] Hertl M, Jedlickova H, Karpati S, et al.Pemphigus. S2 guideline for diagnosis and treatment—guided by the European Dermatology Forum (EDF) in co-operation with the European Academy of Dermato-logy and Venereology (EADV)[J]. J Eur Acad Der-matol Venereol, 2015, 29(3):405-414.
[10] Committee for Guidelines for the Management of Pemphigus Disease, Amagai M, Tanikawa A, et al. Japanese guidelines for the management of pemphi-gus[J]. J Dermatol, 2014, 41(6):471-486.
[11] Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al.Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris[J]. J Am Acad Dermatol, 2007, 57(4):622-628.
[12] Esmaili N, Chams-Davatchi C, Valikhani M, et al.Assessment of the therapeutic benefit of oral predni-solone and common adjuvant therapy in stage Ⅱ of randomized controlled trial study for management of pemphigus vulgaris[J]. Arch Iran Med, 2014, 17(9): 626-628.
[13] Chams-Davatchi C, Mortazavizadeh A, Daneshpa-zhooh M, et al. Randomized double blind trial of pre-dnisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris[J]. J Eur Acad Dermatol Venereol, 2013, 27(10):1285-1292.
[14] Aberer W, Wolff-Schreiner EC, Stingl G, et al.Aza-thioprine in the treatment of pemphigus vulgaris. A long-term follow-up[J]. J Am Acad Dermatol, 1987, 16(3 Pt 1):527-533.
[15] Younger IR, Harris DW, Colver GB.Azathioprine in dermatology[J]. J Am Acad Dermatol, 1991,25(2 Pt 1):281-286.
[16] Doukaki S, Pistone G, Aricò M, et al.Pharmacoki-netic evaluation of mycophenolate mofetil for pem-phigus[J]. Expert Opin Drug Metab Toxicol, 2011, 7(2):237-244.
[17] Doukaki S, Platamone A, Alaimo R, et al.Mycophe-nolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus[J]. J Dermatolog Treat, 2015, 26(1):67-72.
[18] Beissert S, Werfel T, Frieling U, et al.A comparison of oral methylprednisolone plus azathioprine or myco-phenolate mofetil for the treatment of pemphigus[J]. Arch Dermatol, 2006, 142(11):1447-1454.
[19] Beissert S, Mimouni D, Kanwar AJ, et al.Treating pemphigus vulgaris with prednisone and mycophe-nolate mofetil: a multicenter, randomized, placebo-controlled trial[J]. J Invest Dermatol, 2010, 130(8): 2041-2048.
[20] Ioannides D, Apalla Z, Lazaridou E, et al.Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study[J]. J Eur Acad Dermatol Venereol, 2012, 26(7):855-860.
[21] Fleming RA.An overview of cyclophosphamide and ifosfamide pharmacology[J]. Pharmacotherapy, 1997, 17(5 Pt 2):146S-154S.
[22] Sharma VK, Khandpur S.Evaluation of cyclophos-phamide pulse therapy as an adjuvant to oral cortico-steroid in the management of pemphigus vulgaris[J]. Clin Exp Dermatol, 2013, 38(6):659-664.
[23] Rose E, Wever S, Zilliken D, et al.Intravenous dexa-methasone-cyclophosphamide pulse therapy in com-parison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a mul-ticenter prospectively randomized study[J]. J Dtsch Dermatol Ges, 2005, 3(3):200-206.
[24] Sethy PK, Khandpur S, Sharma VK.Randomized open comparative trial of dexamethasone-cyclopho-sphamide pulse and daily oral cyclophosphamide versus cyclophosphamide pulse and daily oral pred-nisolone in pemphigus vulgaris[J]. Indian J Dermatol Venereol Leprol, 2009, 75(5):476-482.
[25] Talar-Williams C, Hijazi YM, Walther MM, et al.Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis[J]. Ann Intern Med, 1996, 124(5):477-484.
[26] Cummins DL, Mimouni D, Anhalt GJ, et al.Oral cyc-lophosphamide for treatment of pemphigus vulgaris and foliaceus[J]. J Am Acad Dermatol, 2003, 49(2): 276-280.
[27] Damiano S, Ciarcia R, Montagnaro S, et al.Prevention of nephrotoxicity induced by cyclosporine-A: role of antioxidants[J]. J Cell Biochem, 2015, 116(3):364-369.
[28] Lapidoth M, David M, Ben-Amitai D, et al.The effi-cacy of combined treatment with prednisone and cyc-losporine in patients with pemphigus: preliminary study[J]. J Am Acad Dermatol, 1994, 30(5 Pt 1):752-757.
[29] Mobini N, Padilla T Jr, Ahmed AR.Long-term re-mission in selected patients with pemphigus vulgaris treated with cyclosporine[J]. J Am Acad Dermatol, 1997, 36(2 Pt 1):264-266.
[30] Ioannides D, Chrysomallis F, Bystryn JC.Ineffec-tiveness of cyclosporine as an adjuvant to cortico-steroids in the treatment of pemphigus[J]. Arch Der-matol, 2000, 136(7):868-872.
[31] Genestier L, Paillot R, Quemeneur L, et al.Mecha-nisms of action of methotrexate[J]. Immunopharma-cology, 2000, 47(2/3):247-257.
[32] Gürcan HM, Ahmed AR.Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid[J]. Br J Dermatol, 2009, 161(4): 723-731.
[33] Tran KD, Wolverton JE, Soter NA.Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients[J]. Br J Dermatol, 2013, 169(4):916-921.
[34] Harman KE, Albert S, Black MM, et al.Guidelines for the management of pemphigus vulgaris[J]. Br J Dermatol, 2003, 149(5):926-937.
[35] Cronstein BN.Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis[J]. Pharmacol Rev, 2005, 57(2):163-172.
[36] Shah N, Green AR, Elgart GW, et al.The use of chlo-rambucil with prednisone in the treatment of pem-phigus[J]. J Am Acad Dermatol, 2000, 42(1 Pt 1): 85-88.
[37] Sugita K, Hirokawa H, Izu K, et al.D-penicillamine-induced pemphigus successfully treated with combi-nation therapy of mizoribine and prednisolone[J]. J Dermatolog Treat, 2004, 15(4):214-217.
[38] Turka LA, Dayton J, Sinclair G, et al.Guanine ribo-nucleotide depletion inhibits T cell activation. Me-chanism of action of the immunosuppressive drug mizoribine[J]. J Clin Invest, 1991, 87(3):940-948.
[39] Dastgheib L, Sadati MS, Baghernejhad M.Assess-ment of the adjuvant effect of tacrolimus in the ma-nagement of pemphigus vulgaris: a randomized con-trolled trial[J]. J Dermatolog Treat, 2015, 26(1):90-93.
[40] Büsing V, Kern JS, Bruckner-Tuderman L, et al.Re-calcitrant pemphigus vulgaris responding to systemic tacrolimus[J]. Dermatology, 2010, 221(2):122-126.
[41] Cohen SN, Lim RP, Paul CJ, et al.Equal efficacy of topical tacrolimus and clobetasone butyrate in pem-phigus foliaceus[J]. Int J Dermatol, 2006, 45(11): 1379.
[1] 刘世一, 陈中, 张素欣. 程序性死亡受体/配体免疫治疗策略在人乳头瘤病毒阳性头颈部鳞状细胞癌中的研究进展[J]. 国际口腔医学杂志, 2024, 51(1): 21-27.
[2] 和子慕, 李风兰. 数字化口腔定位支架在头颈部肿瘤放射治疗中的应用现状[J]. 国际口腔医学杂志, 2024, 51(1): 28-35.
[3] 傅豫, 何薇, 黄兰. 铁死亡在口腔疾病中的研究进展[J]. 国际口腔医学杂志, 2024, 51(1): 36-44.
[4] 韩冲,何东宁,余飞燕,吴东潮. 口腔种植术后疼痛机制及治疗的研究进展[J]. 国际口腔医学杂志, 2024, 51(1): 99-106.
[5] 胡佳,王秀清,卢国英,黄晓晶. 再生性牙髓治疗在成人根尖发育不全恒牙应用的研究进展[J]. 国际口腔医学杂志, 2023, 50(6): 686-695.
[6] 陆磊,王鑫,康泽标,谢富强. 计算机辅助导航手术在复杂颌面部骨折中的应用新进展[J]. 国际口腔医学杂志, 2023, 50(6): 696-703.
[7] 杨冬叶,朱萍,吴淑仪. 舌位的影响因素及临床意义[J]. 国际口腔医学杂志, 2023, 50(6): 723-728.
[8] 戢晓,张岚,黄定明. 牙源性与非牙源性上颌窦炎鉴别诊断及其治疗方案的研究进展[J]. 国际口腔医学杂志, 2023, 50(5): 566-572.
[9] 赵苑汐,苏勤. 根管再治疗中根管充填物去除辅助技术的应用与发展[J]. 国际口腔医学杂志, 2023, 50(5): 581-586.
[10] 宋文鹏,龚蓓文,李聃,曾剑玉,仇玲玲. 机械疗法在正畸治疗中应用的研究进展[J]. 国际口腔医学杂志, 2023, 50(5): 603-612.
[11] 刘婷,武秀萍. 唐氏综合征的口腔-颅颌面表征及治疗进展[J]. 国际口腔医学杂志, 2023, 50(5): 618-622.
[12] 吴思佳,舒畅,王洋,王媛,邓淑丽,王慧明. 根管内感染控制对年轻恒牙牙髓再生治疗的影响及研究进展[J]. 国际口腔医学杂志, 2023, 50(4): 388-394.
[13] 高宇天,苏勤. 酸性氧化电位水在根管治疗中的研究与应用[J]. 国际口腔医学杂志, 2023, 50(4): 401-406.
[14] 范琳,孙江. 微针在口腔医学中的应用[J]. 国际口腔医学杂志, 2023, 50(4): 472-478.
[15] 陈卓,石冰,李精韬. 唇腭裂患者外鼻生长特征的研究进展[J]. 国际口腔医学杂志, 2023, 50(3): 279-286.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 张京剧. 青年期至中年期颅面复合体变化的头影测量研究[J]. 国际口腔医学杂志, 1999, 26(06): .
[2] 刘玲. 镍铬合金中铍对可铸造性和陶瓷金属结合力的影响[J]. 国际口腔医学杂志, 1999, 26(06): .
[3] 王昆润. 在种植体上制作固定义齿以后下颌骨密度的动态变化[J]. 国际口腔医学杂志, 1999, 26(06): .
[4] 王昆润. 重型颌面部炎症死亡和康复病例的实验室检查指标比较[J]. 国际口腔医学杂志, 1999, 26(06): .
[5] 逄键梁. 两例外胚层发育不良儿童骨内植入种植体后牙槽骨生长情况[J]. 国际口腔医学杂志, 1999, 26(05): .
[6] 温秀杰. 氟化物对牙本质脱矿抑制作用的体外实验研究[J]. 国际口腔医学杂志, 1999, 26(05): .
[7] 杨春惠. 耳颞神经在颞颌关节周围的分布[J]. 国际口腔医学杂志, 1999, 26(04): .
[8] 王昆润. 牙周炎加重期应选用何种抗生素[J]. 国际口腔医学杂志, 1999, 26(04): .
[9] 杨儒壮 孙宏晨 欧阳喈. 纳米级高分子支架材料在组织工程中的研究进展[J]. 国际口腔医学杂志, 2004, 31(02): 126 -128 .
[10] 严超然,李龙江. 肿瘤靶向药物载体系统的研究进展[J]. 国际口腔医学杂志, 2008, 35(S1): .